JERUSALEM, March 21, 2017 /PRNewswire/ -- Oramed
Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer
of oral drug delivery systems, announced today the appointment of
Dr. Ronald Law to the newly created
position of Chief Strategy Officer.
"We are very pleased to welcome Dr. Law to Oramed as we head
towards a Phase III trial for our oral insulin capsule, ORMD-0801
and position Oramed for eventual commercialization of oral
insulin. With over 25 years of academic and industry
experience in developing new approaches to treat diabetes and
its complications, Dr. Law will play a vital role in helping to
guide Oramed through our upcoming milestone events," stated Oramed
CEO Nadav Kidron.
Dr. Ronald Law has over 25 years
of academic and pharmaceutical industry experience in diabetes,
cardiovascular disease, and obesity. During his industry career at
Takeda Pharmaceuticals, Dr. Law served in a variety of leadership
and strategic roles spanning US Medical Affairs, Global Medical
Affairs, Corporate Strategic Planning, Global Scientific Affairs
and Intelligence, and R&D External Innovation. Prior to joining
Takeda, Dr. Law was an Associate Professor of Medicine in the
Endocrinology Division, UCLA School of Medicine. Dr. Law received a
PhD in Molecular Biology from UCLA and
a JD from the Whittier College School
of Law. He is a member of the American Diabetes Association and the
American Heart Association.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a platform technology pioneer in
the field of oral delivery solutions for drugs currently delivered
via injection. Established in 2006, Oramed's Protein Oral Delivery
(POD™) technology is based on over 30 years of
research by scientists at Jerusalem's Hadassah Medical Center. Oramed is
seeking to revolutionize the treatment of diabetes through its
proprietary flagship product, an orally ingestible insulin capsule
(ORMD-0801). The Company completed multiple
Phase II clinical trials of ORMD-0801 under an Investigational New
Drug application with the U.S. Food and Drug Administration. In
addition, Oramed is developing an oral GLP-1 analog capsule
(ORMD-0901).
For more information, the content of which is not part of
this press release, please visit www.oramed.com
Forward-looking statements: This press release contains
forward-looking statements. For example, we are using
forward-looking statements when we discuss revolutionizing the
treatment of diabetes with our products. These forward-looking
statements are based on the current expectations of the management
of Oramed only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements, including
the risks and uncertainties related to the progress, timing, cost,
and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval or patent
protection for our product candidates; competition from other
pharmaceutical or biotechnology companies; and our ability to
obtain additional funding required to conduct our research,
development and commercialization activities. In addition, the
following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: changes in technology and market requirements; delays
or obstacles in launching our clinical trials; changes in
legislation; inability to timely develop and introduce new
technologies, products and applications; lack of validation of our
technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and that products may harm recipients, all of which could cause the
actual results or performance of Oramed to differ materially from
those contemplated in such forward-looking statements. Except as
otherwise required by law, Oramed undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with
the SEC.
Company Contact
Oramed Pharmaceuticals
Estee Yaari
Office: +972-2-566-0001 ext. 2
US: +1 844-9-ORAMED
Email: estee@oramed.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oramed-appoints-dr-ronald-law-as-chief-strategy-officer-300426869.html
SOURCE Oramed Pharmaceuticals Inc.